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The Program Cell Death 




Apoptosis plays many vital roles in maintaining organ homeostasis and 
 represents type I programmed cell death. Programmed cell death happens when the 
DNA damage is irremediable and has two important pathways, the intrinsic death 
pathway also known as the mitochondrial pathway, and the extrinsic programmed 
cell death pathway. Any defects in the regulation of these crucial pathways have 
been associated with many disorders, most importantly cancer. Therefore, under-
standing the molecular basis of apoptosis is essential for the treatment of incur-
able cancer. To date, several anti-cancer drugs have been developed by targeting 
anti-apoptotic proteins, which are upregulated in many cancers. Nonetheless, a 
disease progression often time warranted due to the deregulation of several anti or 
pro-apoptotic proteins which also contribute to drug resistance. Hence, it is impor-
tant to understand the maintenance and counteraction of apoptosis and improve 
successful new pharmacological applications of cell death mechanisms for future 
therapies. This chapter discusses the mechanism of apoptosis and emerging prin-
ciples of drug resistance in cancer.
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1. Introduction
Apoptosis is a type of programmed cell death that is a genetically controlled 
process of self-destruction. Upon appropriate internal and external stimulus, 
apoptosis is activated to eliminate the unwanted cells. Hence, damaged cells 
undergo DNA condensation, membrane blebbing, and cell shrinkage which is the 
result of activated caspases and proteases [1]. Programmed cell death (PCD) or 
apoptosis plays an important role to maintain tissue homeostasis. The major aspect 
of the PCD mechanism is the removal of infected, damaged, or mutation carrying 
cells (that cause cell-cycle defects). Apoptosis or type I programmed cell death is 
a well-defined regulated mechanism for the elimination of unwanted cells in the 
later-period of life. Apoptosis happens in a silent-manner, without causing any 
damaging effect on the neighboring cells, tissues, and so extinguish stimulation of 
immunological response [2]. Although, unregulated or deficit form of apoptosis can 
lead to disease conditions such as cancer and autoimmune diseases [3]. Therefore, 
understanding the physiological control of apoptosis is crucial for the development 
of novel approaches to target various diseases. In this chapter, we will provide 
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a brief introduction of apoptosis, the program cell death pathways, the role of 
caspases, the role of PCD in cancer, and anti-cancer therapy.
2. Apoptosis: type 1 program cell death
Apoptosis (will be referred to as PCD) as the name suggest is the targeted 
killing of cells that occurs as a part of homeostasis, development, and pathogenic 
processes throughout life. PCD is well-operated in the physiological processes in 
an orchestrated manner to eliminate any defect in cells or tissues [2, 4]. The three 
well-recognized apoptotic cell disassembly are (i) cell shrinkage, (ii) membrane 
blebbing, and (iii) the formation of membrane protrusions and fragmentation [2]. 
Apoptosis can be triggered via two ways; i) the extrinsic pathway where the cell 
death receptors such as Fas, TNFαR, and Death receptors (DR3, DR4, and DR5) 
bind to their ligands ii) the intrinsic pathway when Bcl-2 family pro-apoptotic 
proteins lead to permeabilization of the mitochondrial outer membrane. Both 
extrinsic and intrinsic pathways are converged on the activation of the caspase fam-
ily, which is responsible for the removal of the damaged cell [5, 6]. The stimulation 
of apoptosis via the extrinsic pathway requires classic ligand-cell-surface receptor 
interaction. Death-receptors-induced extrinsic cell death is mainly critical for the 
function of the immune system [7]. The intrinsic apoptotic cell death starts in a 
cell-autonomous manner. Cellular defects and stresses, such as DNA damage (due 
to toxic agents or defect s in the cell-cycle process) or endoplasmic reticulum (ER) 
stress (caused by accumulated unfolded proteins), leads to apoptosis when the 
damage is further than repair [8].
2.1 The activation of caspases, functions, and regulation
The initiation of apoptosis requires the activation of caspases, which then pro-
mote a cascade of events culminating in the death of a cell. Caspases are a family of 
cysteine proteases, very well conserved proteins playing many vital roles. Caspases 
can be divided into two categories (i) involved in immunity and (ii) the ones 
facilitating apoptotic cell death. These enzymes are expressed inactively inside the 
cell and activated to cleave for specific target substrates [9]. Pro-apoptotic caspases 
cleave a much broader subset of intracellular proteins to intercede cell death via 
apoptosis, on contrary, the caspases those involved in immunity can remove the 
cells via other non-apoptotic mechanisms. Pro-apoptotic caspases are fundamen-
tal for the development, and maintenance of tissue homeostasis [10]. Although 
many different caspases are found in mammals, here attention will be given to 
those which are very well characterized. During program cell death, the activa-
tion of caspases leads to biochemical and structural changes such as condensation 
of chromatin, mitochondria permeabilization, and membrane blebbing which 
are characteristic of apoptotic cell bodies. These essential processes display two 
important functions, firstly, the promotion of cell death and secondly, the elimina-
tion of damaged cells. Caspase-dependent program cell death generally ends with 
cell death [11]. On the contrary, the failure of apoptosis or non-complete process 
cause many disorders, most importantly, cancer. Nonetheless, cells have many other 
regulators that positively or negatively maintaining the activation and/or function 
of caspases [12]. The expression of caspases differs with stimuli type and expres-
sion level. While some caspases are expressed following a death trigger, the others 
are expressed constantly but being in an inactive state [13, 14]. Once the cell senses 
a death signal and/or being damaged the initiator caspases are being activated 
and recruited to the plasma membrane or in the cytoplasm. Upon the cleavage of 
3
The Program Cell Death (Apoptosis) and the Therapy of Cancer
DOI: http://dx.doi.org/10.5772/intechopen.97289
initiator caspases, they activate the destructor caspases. The activation of destructor 
caspases in turn cleave important cellular substrates during program cell death. The 
initiator caspases (caspase −8, −9, and − 10) and destructor caspases (caspase −3, 
−6, and − 7) prefer different cleavage sites [15]. Many of the destructor caspases 
include a cleavage site that is consistent with the peptide substrate specificity. Even 
though, caspase −3 and − 7 contain identical peptide substrate preferences they 
cleave different substrates. Such as Bid, Caspase −6 and − 9, Bid, XIAP, and gelsolin 
are cleaved by caspase −3, while p23 is cleaved by caspase-7 [16]. The destructor 
caspases can cleave more than thousands of substrates to enable program cell death. 
Also, the initiator caspases have many additional important mediators for program 
cell death. The activation of initiator caspase-8 is through the extrinsic program 
cell death pathway which is mediated via death receptors [17]. The other initiator 
caspase-9 is activated by the intrinsic program cell death pathway which is regu-
lated by the apoptosome complex. The active initiator caspases (both −8, and − 9) 
can cleave downstream destructor caspases (caspase −3, −6, and − 7) [18]. The 
activation of initiator caspases can be via several cell-death signaling complexes. 
These different signaling complexes respond to many intra- and extracellular 
events, which induce the recruitment of initiator caspases for the activation process 
[19, 20]. It is important to mention that the interactions of caspase-activation plat-
forms and those caspases indicate a death-fold domain in the proteins. These sorts 
of forms are existing in caspases and adaptor proteins: the caspase-recruitment 
domain (CARD) and death effector domain (DED). There are also different other 
death domains, such as the death domain (DD), and pyrin domain (PYR), which 
are included in some of the activations of caspases but absent on caspases [21]. 
Indeed, death fold domains generally intervene in interactions between proteins via 
homotypic interaction. For example, some extracellular ligands are tumor-necrosis 
factor (TNF) family, TNF-related apoptosis-inducing ligand (TRAIL), and FasL. 
These specific ligands bind to different TNF receptor (TNFR) family, so, upon their 
binding stimulating conformational changes. The specific signaling complex that 
is linked with Fas is DISC (death-inducing signaling complex) and contains FADD 
(Fas-associated death domain), which is a small adaptor protein. TNFR induces 
the activation of several cell-death signaling complexes [22]. Complex IIa involves 
FADD and TRADD, and the other complex IIb involves FADD, and RIPK1, RIPK3 
(receptor-interacting serine–threonine kinases). Both complexes can activate 
caspase-8 and program cell death [23]. Once caspase-9 is activated, the cell death 
stimuli induce Bcl-2 family proteins Bax or Bak and lead to mitochondrial outer 
membrane permeabilization (MOMP) [24]. Later, MOMP is freeing cytochrome-c 
(Cyt-c) and other pro-death factors from the mitochondrial membrane to the 
cytosol [25]. The electrons are carried by Cyt-c in the respiratory chain of healthy 
cells, which function as a co-factor of Apaf-1 in the apoptotic cell’s cytosol. The 
Cyt-c and ATP bind to Apaf-1 to form the apoptosome complex, which results in 
the recruitment and activation of caspase-9 [26]. The active caspase-9 cleaves, and 
in turn, induces the activation of caspase-3. Importantly, this intrinsic program 
cell death pathway is related to a death-receptor pathway through Bcl-2 family 
member, Bid. The cleavage of Bid through death-receptor activated caspase-8 leads 
to truncated Bid, which in turn causes the activation of Bax/Bak-induced MOMP 
([27]. Hence, result in the activation of caspase-9. Caspase-2 activation induced by 
the PIDDosome protein complex involves the Rip-associated protein with a death 
domain (RAIDD) and p53-induced protein with a death domain (PIDD) ([28]. 
The activation of caspase-1 in turn cleaves pro-IL-1b to cause inflammation [23]. 
Different inflammasomes form particular responses to different stimuli such as 
Nod-like receptors (NLRs) including NLRP1, NLRP3, and NLRC4 [29– 31]. The 
NLR inflammasome protein contains an adapter binding domain and adaptor 
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apoptosis-associated speck-like protein (adaptor ASC) containing CARD. Once 
ASC oligomerizes, it, in turn, leads to the recruitment of caspase-1 and activates 
caspase-1 [23]. The activation process of caspases has many violent consequences. 
Thus, the regulation is tightly managed. The cFLIP (cellular FLICE inhibitory 
protein), which is caspase-8’s inactive mimic, binds to signaling complexes that are 
associated with death receptors to repress caspase-8 [32]. XIAP (X-linked inhibi-
tor of apoptosis) is the only active site inhibitor of caspases and contains three 
BIR (baculovirus IAP repeat) motifs. The region BIR2 inhibits the activation of 
destructor caspases, caspase-3 and -7 via two different mechanisms. The first one, 
by binding the catalytic side of caspase-3 and -7, and the second one is by binding 
the newly cleaved protein terminus [33]. Also, the BIR3 motif inhibits the caspase-9 
and blocks the dimerization of caspase-9. Of note, the regulation of caspases can be 
post-transcriptionally by phosphorylation. Several studies reported to inhibit the 
activity of caspase-2, −8, and − 9 [34]. Besides, caspases can play roles in diverse 
signaling pathways by their constant activation, for example, some of the specific 
morphological features of apoptotic cells are due to caspase-intervened activation 
of some actin cytoskeleton modulators such as p21-activated kinase 2 (PAK2), Rho-
associated kinase I (ROCKI) and gelsolin [35–37] (Figure 1).
2.2 The mitochondrial pathway of apoptosis (the intrinsic pathway)
The intrinsic pathway contains the let off of cytochrome c from the mitochon-
dria to the cytoplasm in response to cellular stress [26]. The cellular stress by the 
variety of factors such as DNA damage, deprivation of growth factors, defective 
ER, and several developmental factors activate the intrinsic pathway. In the mito-
chondrial pathway, the cleavage and activation of caspases begin with caspase-9, 
which leads to apoptosome machinery activation [19, 20]. The apoptosis protease-
activating factor1 (APAF1) is a key molecule in the intrinsic pathway of apoptosis, 
besides, an important target for its pro-survival member, and scaffolding the 
assembled apoptosome [38]. In the Intrinsic apoptosis pathway, firstly, cytochrome 
c is discharged from mitochondria and enters into the cytosol, by ending with its 
Figure 1. 
The caspase family proteases and apoptosis. The initial signal on the cell membrane or from the mitochondria 
activates the initiator caspases (caspase-2, caspase-8, and caspase-9), which act on execution caspases. The 
initiator caspases are produced inactively and composed of a pro-domain (containing a CARD or a death 
effector domain [DED]) and, a large and small subunit. On contrary, executioner caspases (caspase-3, 
caspase-6, and caspase-7) are activated by cleavage of the initiator caspases. Thus, dependent on initiator 
signaling. The active caspases including two small and large subunits.
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interaction to APAF1 [39, 40]. The cytochrome c, together with APAF1 forms the 
apoptosome, which leads to inactive caspase-9 monomers into active auto-process 
[26]. The active caspase-9, in turn, leads to activation of downstream effector 
caspases. Further, the mitochondria let off pro-apoptotic proteins includes apopto-
sis-inducing factor (AIF) and endonuclease-G [41]. Cytochrome c is only present 
in the mitochondrial intermembrane in healthy cells, to interact with APAF1, the 
apoptotic stimuli trigger the mitochondrial outer membrane (MOM) permeabiliza-
tion (MOMP) [27]. Hereby, the MOMP conduce to discharge of the entire soluble 
proteins from mitochondrial intermembrane space to the cytosol. Additionally, 
rather than cytochrome c, two important pro-apoptotic proteins which are Smac 
and Omi, were also released meanwhile the above-mentioned procedure. These two 
proteins are crucial for increasing the potential of apoptosome via antagonizing the 
caspase inhibitor called X-linked inhibitor of apoptosis (XIAP) [26, 42]. In the lack 
of Smac and/or Omi, XIAP binding to caspase-9, and inhibits its catalytic activity in 
which also affects the caspase-3 and caspase-7 [42]. The intrinsic apoptotic path-
way is regulated by the Bcl-2 family of proteins [5, 43]. The regulation of MOMP 
is tightly controlled by the Bcl-2 family proteins, they share BH region homology 
with their sequence, function, and structure. The Bcl-2 family can be sub-grouped 
into three categories: the pro-apoptotic proteins, Bax and Bak, play a key role for 
MOMP regulation; the anti-apoptotic proteins, Bcl-2, Bcl-xL, and Mcl-1, these are 
the blockers of MOMP; and the BH3-only proteins, Bid, Bim, Bad and Noxa, which 
are activators of pro-apoptotic proteins and neutralizers for Bcl2 anti-apoptotic 
proteins. Anti-apoptotic Bcl2 proteins control many other cellular processes such as 
autophagy and mitochondrial fusion [24, 44]. Bax and Bak are in charge of the loss 
of mitochondrial outer membrane integrity. Over their activation, they form broad 
oligomers, and by disturbing MOM enduing their entry into MOM. The disturbing 
process still unknown, but this lets off the release of entire intermembrane space 
proteins [45, 46]. Bax and Bak are acting on MOMP involuntarily but importantly at 
least one of them is needed for re-permeabilization of mitochondria. These proteins 
are generally being at an inactive state, and gets activated upon upstream stimuli 
[47–49]. The BH3-only proteins, at least two of them, Bim and active Bid activate 
Bax and Bak via their transient interaction [25, 50–52]. The antagonization of 
MOMP accrued by the Bcl2 anti-apoptotic proteins in which they bind and inhibit 
both Bax and Bak, also BH3-only proteins via interacting with their BH3-only 
domains [53]. The Bcl2 proteins are regulated both transcriptionally and post-
transcriptionally. Especially, via the ubiquitin-proteasome system, the degradation 
of Mcl-1 involve in apoptosis due to many cellular stresses. Over DNA damage, Mcl1 
ubiquitin ligase E3 (MULE) binds to Mcl1 and initiates it catalyzes [54]. Mcl1 is 
phosphorylated via mitogen-activated protein kinase (MAPK) upon cellular stress 
conditions [55]. Also, Mcl1 is degraded with growth factors stimuli such as IL3 and 
the deficiency of phosphoinositide 3-kinase (PI3K)-AKT signaling. This important 
process eases glycogen synthase kinase 3 (GSK3) from AKT inhibition. Then, GSK3 
leads to phosphorylation of Mcl1 and its subsequent degradation [55, 56]. Intrinsic 
pathway signaling with pro-and anti-apoptotic proteins maintain many signaling 
processes in the important point of life and death decision. BH3-only proteins are 
essential upstream sensors of the mitochondrial apoptotic pathway. The regulation 
of several signaling pathways converge on the BH3-only proteins, and therefore, 
control and regulate their expression levels and activity [57, 58]. Such as the acti-
vation of Bid over cleavage by caspase-8 follow up DR ligation [59, 60]. Hereby, 
the Bid mediates the cross-regulation of both extrinsic and intrinsic apoptotic 
pathways. Also, the response to genotoxic stress can be given with Puma and Noxa, 
which are the direct target of p53 [61–64]. Also, the primary apoptotic factor Bim 
similarly can be up-regulated via forkhead transcription factor FOXO3A over 
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cytokine deficiency or due to ER stress to unbind the accumulated proteins [65–67]. 
To this end, the activity of Bad regulated via several kinases’ phosphorylation 
including AKT, which leads to its sequestration through 14–3-3- proteins [68, 69]. 
Also, when Bad is released, it acts against Bcl2 anti-apoptotic proteins over growth 
factor deficiency and/or lacking the AKT signaling [68, 70]. It is noteworthy that 
MOMP is obliged the cell to death even though the caspase activation is hindered 
which might be the conclusion of the loss of mitochondrial function, which causes 
the failure of energy [26, 71]. Some cells can survive under these conditions though 
[26]. Nevertheless, the MOMP activation through its downstream is an important 
point in the regulation of caspases and might be settled. Finally, mitochondrial 
apoptosis can be harassed through the phosphorylation and inhibition of caspase-9 
by acting downstream of MOMP [72].
2.3 The extrinsic pathway of apoptosis
The extrinsic pathway of apoptosis can be initiated through the binding of 
ligands to the death receptors such as tumor necrosis factor receptors (TNFRs) and 
Fas receptor (FasR) on the cell surface [7, 17, 73]. These receptors possess death 
domains at the cytosolic side, which helps in recruiting adaptor proteins such as 
FAS associated via death domain (FADD), and also, for some receptors, TNFRSF1A 
is associated via death domain (TRADD) [74, 75]. The recruitment of these adaptor 
proteins occurs through the interaction of death domains present in both receptors 
and adaptors. The death effector domains of these adaptor proteins have different 
upstream procaspases such as caspase-8 and caspase-10 to form a death-inducing 
signaling complex (DISC), which then promote activation of these caspases 
[17, 76]. The downstream executioner caspases such as caspase-3, caspase-6, and 
caspase-7 activated through their upstream caspases to execute cell death [77]. The 
main feature of apoptosis is the lack of systemic damage to neighboring cells during 
its initiation and clearance of the dead cells. This feature of apoptosis is provided 
by the attentive wrapping of the cell membrane around the fragmented cell by 
forming apoptotic bodies. The release of ATP (adenosine 5′-triphosphate) and UTP 
(uridine- 5′-triphosphate) from apoptotic bodies display a signal for macrophages, 
leads to the migration of macrophages to the apoptotic site [78]. Besides, apoptotic 
cells also expose the eat me signal most likely phosphatidylserine (PtdSer) on their 
surface, which initiates phagocytes to engulf the must-remove cells [79].
3. Apoptosis and cancer
Cancer is a multi-complex disease arising from mutation of tumor suppressor 
or oncogenes, which can be due to impairment of several signaling pathways and 
associated with apoptosis [80]. The evasion of apoptosis is an important sign of 
cancer, which mostly results in a very high level of resistance to many chemo-
therapeutic agents. Therefore, attention has been given to apoptotic proteins and 
became the most attractive anti-cancer target for effective treatment. The resis-
tance against apoptosis is seen in many types of cancers, and required much higher 
doses of drugs to overcome the resistance, which increases the risk of “off-target” 
negative effects [81]. Apoptosis is also a very complex system with its regulation 
and/or function via several proteins, kinases, and links with several pathways 
might provide important therapeutic benefit for novel approaches to treat cancer. 
A better understanding of apoptotic pathways and their alteration in cancer cells 
had the attention of the development of pro-apoptotic agents. In cancer cells, 
cell death has been reported for a long time and associated with cancer therapy 
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due to the designation of killing malignant cells by chemo- and/or radiotherapy. 
Unfortunately, this also leads to the death of normal cells along with cancer cells  
[80]. Kerr et al. reported that radiation increases the rate of apoptosis in cancer 
cells. Therefore, apoptosis-associated directly with the development of cancer cells 
in humans. Most importantly, it can also promote resistance to the therapies which 
aim to kill cancer cell by targeting apoptosis [2]. In healthy cells, the recognition of 
damage leads to activation of program cell death, which ending up with their elim-
ination by killing themselves. Such as the activation of tumor suppressor p53 can 
activate apoptosis inducers including Puma and Noxa, in normal cells [61, 62, 64]. 
Thus, the un-endowed cells which are not able to eliminate themselves may cause 
an accumulation of genetic damage. The oncogenes (e.g. Myc) induced apoptosis 
is a very crucial protective mechanism against cancer development, controlled by a 
p53-dependent pathway, activated in response to abnormal mitogenic signals. Such 
as the cells overexpressing the apoptosis inhibitor Bcl2 or have damage in the p53 
gene are incapable of this removal process including cancer cells. The loss of func-
tion mutations in the p53 tumor suppressor gene causes defection in the apoptotic 
mechanism and also impacts its tumor-suppressive functions, which involving 
DNA repairment, cell-cycle arrest, and cell senescence [82, 83]. Also, the incapable 
cells with an additional mutation can lead to atypical cell proliferation. Such as 
chromosome translocation which ends up with over-expression of c-Myc, then 
will lead to quick malignant cell growth. Of note, this explains that the defects 
in apoptotic mechanism such as over-expression of apoptosis inhibitor Bcl-2 and 
unregulated cell proliferation due to c-Myc overexpression in the development of 
lymphoma [82, 84, 85].
Understanding of extrinsic apoptotic pathway on death receptors especially 
on TRIAL signaling, including TRAIL-1 and -2, shown to lower toxicity com-
pared to TNF or FAS signaling were targeted. The lowering expression levels 
of TRAIL receptors via recombinant human TRAIL-R1 and -R2 opened up 
an important therapeutic window. The tumor cells pre-dominantly signal via 
TRAIL-R1 and -R2, and the expression of these receptors displayed that they do 
not behave as an indicator of favored receptor signaling [86]. The higher expres-
sion levels of these receptors have been found on brain tissue and hepatocytes 
[87, 88]. However, these findings opened up several windows about the use of 
TRIAL in the clinic which has been reported notable apoptotic cell death in 
primary hepatocytes. These findings underlining the importance of selective 
models to evaluate appropriate drug combinations and their potential on- and/or 
off-target adverse effects. A study by Von Karstedt et al. in KRAS mutant cancers, 
known to have an elevated level of TRAIL-R2 expression shown that triggering 
TRAIL signaling is worsen the development of cancer, and metastasis [89, 90]. 
Several other studies in different cancers such as pancreatic cancer also shown 
that TRIAL-R2 signaling interacts with the miRNA processing complex and leads 
to the inhibition of the maturation of mRNA, called let-7. The result of TRAIL 
R2-miRNA interaction displayed an up-regulated level of let-7 transcriptional 
target genes which also prompt cancer development [91]. The sublethal concen-
trations of TRAIL were shown to induce the activation of caspase-8 dependent 
apoptotic nucleases, which leads to increased mutations caused by DNA damage 
in surviving cells [92].
The IAP proteins which are downstream of DRs and Bcl2 family proteins are 
excessively expressed in cancer cells, therefore associated with cancer develop-
ment and as well as resistance to therapies. The involvement of cIAPs has also been 
associated with the regulation of the NF-KB pathway. The lack of cIAPs leads to an 
increase of inflammatory cytokines including TNF family and IL6, IL8, IL10, and 
Mcl1, which are effectively involved in systemic inflammation [93]. Nevertheless, 
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these cytokines have also been reported to be increased in cancer progression due to 
their link with inflammation which causes to include immune cells to the cancer site 
and prompt the tumor development (Figure 2).
3.1 p53 phosphorylation: is it a driver to cell death?
DNA damage comprises different causes that involve cell stress, mutations, toxic 
agents, or genomic lesions. Upon damage, the confrontation of cells to damage lead 
to their potential responses to repair the damage or eliminate the harmed cells by 
apoptosis. Usually, the response of the damaged cell fate differs from strength to the 
Figure 2. 
Molecular mechanisms of intrinsic and extrinsic apoptotic signaling pathways activation. a. the activation of 
intrinsic apoptotic signaling pathway through cellular stress (ER), and deprivation of growth factor (DNA 
damage). This alteration promoting the activation of pro-apoptotic members of the BCL-2 family, including 
BIM, PUMA, BAD, or NOXA. The BH3-only proteins bind and therefore, neutralize BCL-2 pro-survival 
proteins, involving BCL-2, BCL- XL, MCL-1, and BCL-2- related protein A1. Thus, releasing the important 
effectors of apoptosis signaling, such as BAK and BAX, which then unite into big complexes and lead to 
incompliance in the mitochondrial outer membrane. Afterward, this results in the free off cytochrome c 
and SMAC, which are apoptogenic factors. Some of BH3- only proteins (BIM and PUMA) recently have 
been reported to bind and promote the activation of MOMP. Also, cytochrome c binding to APAF1 leads 
to the formation of the apoptosome complex. Caspase-9 is activated in this apoptosome complex, and later 
proteolytically causes the activation of both caspase- 3 and caspase-7. The caspase inhibitor XIAP activity is 
blocked by SMAC. b. Extrinsic apoptotic signaling is stimulated through the activation of DRs, for example, 
the activation of FAS via FAS ligand (FASL). This cause the pro-caspase 8 recruitment to the death receptor 
by the adaptor protein FADD, and ending up with the formation of the DISC, which is an important 
catalyzer for the caspase-8 activation. The activation of caspase 8 promotes cell killing, in two ways: i) via 
direct activation of caspases 3 and 7, or ii) by indirect activation of the BH3 only protein BID into tBID, thus 
linking with the intrinsic apoptotic signaling pathway. Effector caspases can be activated in two ways, either 
by cleavage of hundreds of intracellular proteins to promote the conventional apoptotic morphology and to 
avoid the efflux of intracellular DAMPs which can result in inflammatory responses. In addition, effector 
caspases either directly or indirectly can lead to activation of ROCK-1 kinase, which is important for plasma 
membrane blebbing by actin contraction and caspase-activated DNAse (CAD), which cause inter-nucleosomal 
DNA cleavage and thus chromatin condensation. These effector caspases also can proteolytically lead to the 
inactivation of lipid flippases including ATP11, and also can activate the lipid scramblase such as XKR8. 
Altogether, this results in the exposure of PtdSer on the cell membrane. Therefore, this is called an ‘eat me 
signal’ for phagocytic cells and ending up with the engulfment of cells that are undergoing apoptosis [94].
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content of DNA damage, and different signaling pathways are activated. The dif-
ferent cellular decision-making process is guided with specific signaling molecules 
at the molecular level [95]. The tumor suppressor p53 plays a key role in response 
to DNA damage and involve in the cellular decision-making process, in turn, found 
to prompt DNA repair by shutoff the cell cycle to allow time for the repairment and 
restore genome stability [96]. However, it remains unknown still that how p53 does 
different cell-fate decisions, activate different target genes, and at a non-transcrip-
tional level have an effect in the cytoplasm of MOMP [97]. The phosphorylation 
of p53 at Ser15 and Ser20 occurs over immense DNA damage and these are critical 
sites for stabilization of p53 [98]. Importantly, there is a specific phosphorylation 
site which is Ser46 and selectively associated with the activity of cell killing caused 
by genotoxic stress. These crucial different phosphor-sites of p53 might improve 
the understanding of the function of specific phosphorylation sites. Many studies 
focused on the phosphorylation of p53 at Ser46 which modulates the target gene 
transactivation and it has been implicated to potentiate cell death transcriptionally 
and also, non-transcriptionally [95]. The transactivation of significant pro-apop-
totic p53 target genes including BAX, NOXA, p53AIP1, PTEN, and AKT kinase, 
which are all up-regulated over p53 Ser46 phosphorylation [63, 99–101]. How this 
different transcriptional effect occurs and which mechanisms are evolved is an open 
question? The specific role of the p53 Ser46 phosphorylation site in making a cell-
fate decision upon cell death leads to the thought of its disturbed regulation might 
cause cancer cell resistance to therapy. The deregulation of p53 Ser46 kinases in 
cancer cells could be caused by many factors involving mutations, mis-localization, 
lower expression level, and disturbed kinase activity. The mutations of p53 at Ser46 
have been reported with 1.4–1.6% rates in different human cancer types including 
breast, colorectal, lung, and stomach. Besides, the down-regulation of several p53 
Ser46 kinases are reported such as ATM, DYRK2, HIPK2, and p38𝛼 in different 
tumor types [63, 102–104]. Although, since the regulation of the kinase relies on 
p53 Ser46 activity, their specific potentials and activities is a challenging task.
3.2 The pro-oncogenic roles of apoptosis
The deregulation of apoptosis is a feature of cancer cells. Apoptosis is a 
tumor suppressor mechanism in cancer cells. Hence, the dysregulation of 
apoptosis causing uncontrollable cancer cell-survival [105]. Besides, the tumor-
suppressive effects of apoptosis, also, suggested having pro-oncogenic functions. 
The maintenance of aggressive tumors by apoptosis has been described in the 
literature. The term tumor aggressiveness defined with increased proliferation, 
and metastatic features of cancer cells. Such as apoptotic stresses are maybe the 
reason for aggressive tumor development. Therefore, have pro-oncogenic roles 
in cancer development and aggressiveness [106, 107]. Importantly, this opens 
several questions about the beneficial effects of apoptosis in cancer therapy, 
since strategies aim to trigger apoptosis [108]. Apoptosis-induced prolifera-
tion (AIP) is an important compensatory proliferation form, which helps to 
eliminate damaged cells and maintain tissue homeostasis. Caspase-dependent 
inflammation and repressed AIP activity might lead to tumor development. One 
important mediator of AIP is Prostaglandin-E2 (PGE-2), and functioning as a 
trigger of tumor proliferation in apoptotic cells [109]. The regulation of tumor 
cells by PGE-2 through caspase-3 dependent manner is an important strategy 
to treat melanoma. Here, the dying cells trigger the growth of living-cells after 
cytotoxic therapy [110, 111]. Therefore, targeting PGE-2 to enhance the response 
to therapy might help to overcome the resistance in cancer cells, when designing 
cancer therapies [112].
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3.3 The oncogenic roles of apoptosis
Apoptotic cells release the “eat-me” signal which is a signal for phagocytosis. 
These dynamic signals are including fractalkine (FTK), phosphatidylserine (PS), 
nucleotides ATP, and UTP [113, 114]. These signals are responsible for immune 
cell activation. Such as the effects of FTK associated with cell migration, and 
angiogenesis. Also, these signals by apoptotic cells are thought to induce inflam-
mation. Somehow, in the occurrence of normal apoptotic cell death, inflammation 
is prevented by efferocytosis. The mechanism of efferocytosis is to eliminate the 
apoptotic cells by immune cells, macrophages. Importantly, it also plays a key role in 
cancer cells by creating an immunosuppressive effect to organize several signaliza-
tion events between tumor cells [115]. For example, a study by Ford and colloquies, 
in 2015, showed that apoptotic cancer cells induce tumor growth and angiogenesis 
in B-cell lymphoma and also, malignant melanoma [116]. In conclusion, the effects 
of apoptotic cells in their microenvironment is changed upon their features. The 
studies that suggest apoptotic cell involvement might play important role in signal-
ing events due to their environment and features. Of note, it remains unknown how 
they do these roles, therefore, more studies are needed to clarify this point.
4. The therapeutic approaches to cancer
The question what happens when apoptotic machinery is impaired? The answer 
is impairment of apoptosis results in uncontrolled cell proliferation, tumor devel-
opment and progression, and resistance to anticancer therapeutics [117, 118]. The 
deregulation of apoptosis is not only causing the development and progression of 
the tumor but also lead to resistance to therapeutic approaches [80]. Cancer cells 
can promote drug resistance to several treatments, which target several different 
molecular signaling. So many cancers present an internal resistance to chemo-
therapy, without previous exposure to anti-cancer agents. Therefore, the beginning 
response to cancer treatment is weak. Furthermore, several tumors might also gain 
drug resistance because of chemotherapy [119–122]. Among many intrinsic and 
gained drug resistance are increased drug leakage, defective inflow transporters, 
changes in the function of drugs and their targets, drug inactivation metabolically, 
drug compartmentalization, increased activity of DNA repairment [120, 123–126]. 
To improve therapeutically new approaches, the understanding of these signaling 
pathways is required to progress cancer therapy and more importantly get over the 
resistance. Besides, targeting the apoptotic signaling events that are involved in 
resistance may improve a valid strategy to increase the cell sensitivity of cancer cells 
to apoptosis and overcome the failure of therapeutic difficulties.
4.1 The role of Bcl2 family proteins in cancer and drug resistance
The Bcl-2 family proteins contains at least one Bcl-2 homology (BH) domain 
[127–129]. The different BH-domains exist, but especially BH-3 is crucial to form 
several BCL-2 protein complexes that govern the result between survival and death 
[130–133]. These interactions between BH3-BH3 are also important to antagonize 
pro-survival complexes. The increased level of anti-apoptotic Bcl-2 family proteins 
is associated with carcinogenesis. Such as the transgenic mice model that over-
express Bcl-2 shown to develop tumors spontaneously [134]. However, the high 
expression of Bcl-2 was also reported to cause a shift in the balance of cancer cells 
through survival and also lead to resistance to chemotherapy [135]. Overexpression 
of Bcl-xL, another member of the Bcl2-family is also associated with colorectal 
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cancer [136]. This unbalanced expression of Bcl-2 family proteins confers failure 
of apoptosis and resistance to cancer therapies [137]. Especially, overexpression of 
anti-apoptotic proteins such as Bcl-2 and Bcl-xL is correlated with several cancers 
including ovarian and breast cancer [138, 139]. On the other side, an increased ratio 
of Bcl-2/Bax is associated with chronic lymphocytic leukemia (CLL) [140].
4.2 The role of BH3-mimetics as a potential therapeutic option for cancer
Bcl-2 family proteins control the intrinsic apoptosis pathway toward protein–
protein interactions, which including all BH-3 domains [141, 142]. Currently, the 
therapeutic approaches mostly focused on mimicking and target the BH-3 only 
proteins. BH-3 mimetics are small molecule compounds and bind to anti-apoptotic 
Bcl-2 proteins. Therefore, inhibit their activity and promotes apoptosis [133, 143]. 
Of note, BH-3 mimetics can start apoptosis by leading to activation of Bax/Bak or 
by inhibiting anti-apoptotic Bcl-2 family proteins [142]. Between a variety of BH-3 
mimetics that have been generated, ABT-737 and ABT-263 (Navitoclax) showed 
the most promising antitumor efficacy by engaging anti-apoptotic Bcl-2 family 
proteins. Both drugs are shown to engage to Bcl-2, Bcl-Xl, and Bcl-w. Somehow, the 
use of Navitoclax showed to cause thrombocytopenia by inhibition of Bcl-xl, as a 
major adverse effect [144, 145] These side effects lead to exclusion of Navitoclax 
as an effective chemotherapeutic drug and required new findings more selective 
for Bcl-2 inhibitors, so can induce cell death without causing critical side effects. 
Indeed, ABT-199 (Navitoclax) was subsequently developed to replace Navitoclax, 
as a highly selective Bcl-2 inhibitor. Venetoclax binds with high affinity to Bcl-2 
and a lesser extent to other Bcl-2 family proteins including Bcl-xl and Bcl-w. Also, 
Venetoclax lacks off-target effects on BCL-XL [146]. Altogether, the pre-clinical 
experience with venetoclax and together with combining BCR signaling inhibitors 
were shown to be very promising with significant efficacy in the patient popula-
tion Chronic Lymphocytic Leukemia (CLL) and Diffuse Large B-cell Lymphoma 
(DLBCL). The study by Binu Sasi et al., in 2019, showed that fostamatinib and 
ibrutinib can sensitize DLBCL cell lines to venetoclax, which marks the impor-
tance of combination approaches. In conclusion, the findings provided a rational 
explanation for testing the use of combination therapy with venetoclax and selec-
tive BCR inhibitors in clinical use in DLBCL [147]. The progress of research is 
underlying the continuous role of Bcl-2 family inhibitors as promising and effective 
anticancer therapeutic agent. However, another small molecule BDA-366 (BH4 
domain inhibitor) is also recently described as a promising approach in anticancer 
treatment. The potent effects of BDA-366 have been experimentally validated in 
both in vitro and in vivo, by showing significant anticancer activity [148]. Lastly, a 
very innovative strategy again comes from Bcl-2, the Bcl-2 gene is known to be rich 
with GC sequence which is placed in the promoter region, and has the potential to 
form G-quadruplex structures. Thus, is playing a role as a transcriptional repressor 
element and these G-quadruplex-specific ligands are capable of regulating Bcl-2 
transcriptionally [149, 150].
4.3  Up-regulation of Bcl-2 (pro-apoptotic) family proteins to overcome 
resistance in cancer cells
The up-regulated expression level of anti-apoptotic Bcl-2 proteins might be 
possible be neutralized by increasing the expression of pro-apoptotic Bcl-2 proteins. 
Puma is an important BH-3 protein, having a key role in mediating pro-apoptotic 
p53 function and help to release p53 from inactive forms with Bcl-Xl. Hereby, freed 
cytosolic p53 can activate Bax and Bak, which results in stimulation of apoptotic 
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signaling through MOMP [44, 151]. p53 increases the expression of pro-apoptotic 
protein level, called ARTS, and counteracts Bcl-xl to induce apoptosis [152]. Hence, 
the inhibition of p53 antagonists such as Mdm-2 can cause an increased level of p53, 
induce pro-apoptotic protein expressions. Additionally, reduction of pro-apoptotic 
BH-3 only protein levels can also lead to drug resistance. This effect might be due to 
its interaction with BCL-2 anti-apoptotic proteins in cancer cells [153].
4.4 Therapeutic approach to target death receptor
There are different reasons and ways cause the failure of apoptosis or leading 
to resistance. Including altered death receptor signaling, an unbalanced level of 
pro-and anti-apoptotic proteins lowered caspase role and disrupted p53 function. 
Impairment of the death receptor signaling pathway is associated with many sorts 
of tumors, showing the importance of the Fas–FasL system and/or the abnormal 
level of cytosolic components of this pathway such as FADD can improve the tumor 
conversion [154, 155]. Transcriptionally silencing of Fas is familiar with oncogenic 
events in the epithelial conversion, the mutation in this gene linked with B-cell 
germinal center-derived lymphomas [156]. However, the lack of expression level of 
FADD is a common sign in acute myelogenous leukemia (AML) which leads to che-
motherapy resistance [154, 155, 157]. Furthermore, the low and/or lack of caspase-8 
expression have been reported in numerous other cancers including neuroblastoma 
and small cell lung cancer [158–160]. However, the induction of apoptosis by trig-
gering the death receptor pathway might be an important promising approach to 
overcome the resistance to therapeutic agents. An important therapeutic approach 
that confers the TRAIL ligand which induces apoptosis in many different cancer 
cell lines [161]. TRAIL-induced apoptosis, an important mechanistic strategy that 
has a harmful effect against cancer cells and leads to several different approaches to 
develop agonistic-featured antibodies against TRAIL death receptors and/or several 
soluble recombinant derivatives of TRAIL [162, 163]. On the other side, increasing 
the sensitivity of malignant tumors to TRAIL-induced apoptosis is crucial to design 
new promising molecules to target and activate caspase-8 [164]. Importantly, the 
validation of in silico screening some small molecules which promote caspase-8 
activation have been reported. In many different cancer cell lines including leuke-
mic cells, the CaspPro molecule is shown to be very promising, and shown to induce 
not only caspase-8 activation but also caspase 3 activation, and leading to apoptosis 
in the presence of TRAIL [163–165].
Among other therapeutic approaches, another important strategy is targeting 
IAPs. Through the use of antisense oligonucleotides and small-molecule inhibitors 
very potential anticancer therapeutic approach has been developed. In ovarian 
cancer, the supplementation of antisense agents targeting XIAP through an adeno-
viral vector was displayed to reduce the expression level of XIAP and underlined 
its remarkable effect to induce apoptosis [166]. Besides, in lung cancers also its 
effect has been proven by showing that it increases cell sensitivity to radiation 
treatment [167]. In this regard, by inhibition of XIAP through the use of specifi-
cally designed oligomers also displayed to promote the activation of caspase-3, 
increasing the apoptotic effect of TRIAL in different cancers such as prostate cancer 
[168]. Furthermore, the SMAC mimetics are also shown to trigger apoptosis and/
or increase the sensitivity of cancer cells to different therapies. These molecules 
induce caspase activation through the neutralization of XIAP-mediated caspase 
inhibition [169]. The successful therapeutic approach relies on the capability of the 
tool to trigger apoptosis mainly by two approaches, i) targeting overexpressed anti-
apoptotic Bcl-2 family proteins, or ii) triggering the activation of pro-apoptotic 
molecules.
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5. Conclusion remark
In conclusion, the main hallmark of cancer is the intrinsic or requisite resis-
tance to apoptosis, and the evasion of apoptotic cell death can be part of cellular 
response to stressful stimuli. Based on our understanding of how the dysregulation 
of the apoptosis pathway leads to cancer, approaches to target anti-apoptosis Bcl-2 
family proteins have proven to be effective in the treatment of cancers, especially 
lymphatic cancers. However, cancer cells often outsmart these therapeutic interven-
tions by modulating the expression of other molecules of apoptosis. Novel combi-
nation approaches are warranted to overcome this drug-induced resistance. More 
importantly, the new perspective and pieces of evidence are needed for powerful 
approaches to overcome drug resistance in cancer cells in clinical use. Therefore, 
the current knowledge needs a further understanding of how different cellular 
stresses trigger anti-apoptotic mechanisms, and how these effects lead to apoptotic 
 resistance in cancer cells.
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